Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Geneoscopy Expands Leadership Team to Support ColoSense™ Rollout and Advance Precision IBD Solutions

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, has appointed Matt Sargent as Chief Commercial Officer and Tyler Aldredge as Vice President of Operations to support the commercialization of ColoSense, which recently received FDA approval for colorectal cancer screening (CRC) in average-risk individuals over 45 years of age. Sargent and Aldredge will also help expand the company's RNA platform to inflammatory bowel disease (IBD) diagnostics, offering providers and patients a promising tool for predicting and monitoring therapeutic effectiveness.

“We are pleased to welcome Matt and Tyler to the Geneoscopy team at such a pivotal time for the company,” said Andrew Barnell, Geneoscopy’s co-founder and Chief Executive Officer. “Matt’s proven experience commercializing oncology diagnostic products and Tyler’s expertise in operational process and management will be critical as we accelerate toward bringing ColoSense to market and hit several key clinical and development milestones with IBD.”

"As I step into this new role, I look forward to collaborating with our talented team and partners to realize the full potential of our innovative RNA technology and bring valuable solutions to patients and providers,” said Sargent. “With our focus on advancing ColoSense and expanding precision diagnostics for IBD, we are poised to make a meaningful impact in improving outcomes for the 60-70 million Americans suffering from GI diseases.”

Sargent brings 20 years of experience leading high-performance commercial teams in the oncology space. Most recently, he served as Chief Business Officer at Harbinger Health, responsible for business development related to the company’s blood-based cancer early detection test. Before Harbinger Health, he was Vice President of Commercial Oncology at Hologic, responsible for sales, commercial strategy, and business development for the CLIA oncology diagnostics service business, following Hologic’s acquisition of Biotheranostics, where he served as Chief Commercial Officer.

Aldredge brings more than 30 years of leadership, operations management, and operational quality experience across a range of multi-site laboratories and facilities, along with extensive proficiency in process development and laboratory set-up, scale-up, and automation. Before joining Geneoscopy, Aldredge served as Vice President of Lab Operations, Facilities, and Real Estate with Bluerock Therapeutics. He is a member of the Society for Laboratory Automation and Screening and serves on the Lab-of-the-Future Committee.

Sargent and members of Geneoscopy’s leadership team will attend Digestive Disease Week 2024 in Washington, D.C., May 18-21 (booth #1407). Additionally, two posters will be presented at the meeting, demonstrating the capabilities of Geneoscopy's stool-based RNA platform:

  • Stool-derived eukaryotic RNA assay approximates disease activity index and predicts therapeutic response in patients with Crohn’s disease on advanced therapies
    • Date & Time: May 18, 2024, from 12:30 PM to 1:30 PM
  • Development of a second-generation multi-target stool RNA test (ColoSense 2.0) for colorectal cancer screening
    • Date & Time: May 19, 2024, from 12:30 PM to 1:30 PM

About Geneoscopy, Inc.

Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company’s FDA-approved ColoSense™ test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.